Navigation Links
Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
Date:2/9/2011

ate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities may not grant or may delay approval for our product candidates; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; the potential that we will need additional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2009. You are cautioned not to place undue reliance on these forward
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... DUBAI , UAE, June 2, 2015 /PRNewswire/ ... to create the first, mainstream reporting standard for ... Principles. The next big step in CSR: The Islamic ... Launched only last month, the Islamic ... from across the Islamic world.  The latest members ...
(Date:6/1/2015)... -- LaunchPad Medical, LLC announced today that it has ... Corporation,s (NYSE: SYK ) bone adhesive technology, ... Under the terms of the agreement, LaunchPad has ... this technology which is covered by four issued ... from multiple pre-clinical animal studies.  LaunchPad will seek ...
(Date:6/1/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the three months ended March ... in Canadian dollars unless otherwise stated. ... despite its limited financial resources," stated Mr. ...
Breaking Medicine Technology:Call for Partners: Islamic CSR 2LaunchPad Medical Executes Definitive License Agreement with Stryker for Novel Bone Adhesive Technology 2Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
... Minn., May 29, 2012 /PRNewswire-iReach/ -- MD ... marker for ankylosing spondylitis (AS): HLA-B*2705 . The ... in flow cytometry, tissue staining and immunoprecipitation. ... (AS) is a chronc inflammatory arthritis. It is characterized ...
... Corp. today announced it is a founding member of ... HP for its server rack technology developed to the ... performance and reliability of HP ProLiant Generation 8 (Gen8). ... in the new HP ProLiant Gen8 servers, transforms data ...
Cached Medicine Technology:MD Bioproducts releases HLA-B27 subtype specific antibody. 2MD Bioproducts releases HLA-B27 subtype specific antibody. 3Rittal Corp. Joins the HP ProActive Insight Architecture Alliance 2
(Date:6/2/2015)... June 02, 2015 Amercanex, the ... Jim Miller to become Amercanex’s new Chief Technology ... marketplace in which cultivators, wholesale distributors and retail ... in a fully transparent intra-state market. , Jim ... the financial technology space, helping innovative technology companies ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Thermi, ... technology company has successfully transitioned into its new ... due to the company’s continued rapid worldwide expansion ... comprised of over 25 Thermi employees, including those ... development teams. , “As one of the fastest ...
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... North Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... American publisher of audit, compliance and risk ... of a new online risk management effectiveness gap-improvement ... reduce the effect of uncertainty on objectives. Organizations ... but they improve their capabilities to do this ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Marcy Herrmann as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than 700,000 ... an honor to present Marcy with this distinction,” said ...
Breaking Medicine News(10 mins):Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... registration for the American Water Works Association,s Annual Conference and Exposition ... the conference and save up to $200 in registration fees. ... ... deadline for early registration for the American Water Works Association,s ...
... a plan to deal with market stress, he saidNEW ... deal with the stress of the market, psychiatrist and ... recent gathering of the Greenwich Roundtable, a non-profit research ... alternative investments.Kiev, president of Kiev Consulting, coaches institutional traders ...
... showed no benefit for brain-wasting disorders such as Creutzfeldt-Jakob ... drug quinacrine doesn,t prolong survival of patients with brain-wasting ... say. , Currently, there is no way to prevent ... -- an oral drug used to treat malaria and ...
... LONDON, March 11 , - With ... Smoking Day, three ,mini, entrepreneurs today went,head-to-head to win a GBP2,000 ... challenge, the school children faced their toughest,challenge yet when they presented ... smoking. , Shannon Stokes, 9, from Neith, ...
... attack: prevention has improved, mortality rates are down, hospitalisation ... from the Framingham Heart Study, which compared acute ... over four decades, has proposed an explanation for the ... stable rates of hospitalisation.(1) The study found that over ...
... sites offers recruitment and career opportunities to address ongoing needs., ... ... slowing economy and as unemployment climbs, many healthcare fields are still ... jobs in February, with a gain of 27,000. Job growth occurred ...
Cached Medicine News:Health News:ACE09 Early Registration Ends March 21 2Health News:Psychiatrist and Trading Coach Dr. Ari Kiev Addresses Greenwich Roundtable 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 2Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 3Health News:"I'm In" - Duncan Bannatyne Judges "Switch Ash for Cash" Schools Competition 4Health News:Explaining trends in heart attack 2Health News:Healthcare Industry Continues to Post Gains in a Down Economy 2
... The introduction of the AMO ... in Phaco technology; The combination of ... in complete control of fluidic conditions ... as the "smart Pump" orchestrates the ...
... the features of phaco systems costing much ... maintenance. Small, light and tough enough to ... cost reusable tubing kit can be auto-claved ... a price objection to purchasing a modern ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
The world's first and only laser surgical device combining irrigation and aspiration comfortable and precisely. This innovative combination is used for advanced small incision intraocular surgery....
Medicine Products: